Temasek Holdings has reduced its stake in Amyris Biotechnologies by 1.12 per cent, to 39,340,967 shares. The Singapore based fund now owns 36.12 per cent of the industrial bioscience materials company.
Currently, Amyris has a market capitalisation of $160.65 million
The company focuses on leveraging its bioscience technology to develop and provide renewable compounds for different industries. The firm applies an industrial bioscience technology platform to provide alternatives to select petroleum-sourced products that are used in the consumer care, specialty chemical and transportation fuel sectors.
According to an Octafinance report, 54 hedge funds and institutional investors own shares in Amyris, with the institutional ownership of the company in Q1 2015 is high, at 31.56 per cent of the shares outstanding. A total of four funds have opened new positions in Amyris, while 13 have increased their holdings
First Republic Investment Management is the most positive institutional investor on Amyris, with it being at less than 0.01 per cent of its stock portfolio. Temasek Holdings Private Ltd is another positive institutional investor, with Amyris composing 0.19 per cent of its stocks portfolio.
Founded in 2003, Amyris’s commercialisation efforts have been focused on a renewable hydrocarbon molecule called farnesene (Biofene), which forms the basis for a range of products including, emollients, fragrance oils and diesel fuel.
While Amyris’s platform can use a wide variety of feedstocks, it has initially focused on Brazilian sugarcane and has entered into various contract manufacturing agreements to support its commercial production needs. Amyris has two principal operating subsidiaries: Amyris Brasil for production in Brazil, and Amyris Fuels.